Published online Dec 18, 2021. doi: 10.5500/wjt.v11.i12.512
Peer-review started: July 26, 2021
First decision: September 2, 2021
Revised: September 25, 2021
Accepted: November 14, 2021
Article in press: November 14, 2021
Published online: December 18, 2021
In solid organ transplants, one should be aware of the potential risk for tuberculosis, usually because reactivation of latent tuberculosis infection (LTBI).
Dealing with tuberculosis risk is especially difficult in countries with high endemic rates. In liver transplant recipients, we also have to deal with hepatotoxicity associated with the treatment regimens for LTBI.
The aim of this study was to evaluate the frequency of LTBI in liver transplant patients and treatment-related issues.
This is a retrospective analysis of a cohort of cirrhotic patients aged ≥ 18 years who underwent liver transplantation at a high-complexity teaching hospital from January 2005 to December 2012. LTBI diagnosis and treatment were analyzed.
The prevalence of LTBI was lower than expected, probably due to low TST sensitivity in patients with impaired liver function. In addition, the initiation and completion of LTBI was limited by difficulties in the management of patients in the presence of elevated liver enzymes and a potential risk of hepatotoxicity.
The prevalence of LTBI was lower than expected, and the initiation and completion of LTBI treatment was limited by difficulties in the management of these special patients.
It is necessary to search for other criteria to indicate the treatment of LTBI for patients submitted to liver transplantation, and further research is necessary to develop an effective and well-tolerated alternative therapeutic strategy for LTBI.